BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?

The article compares Black Diamond Therapeutics (BDTX) and Cullinan Therapeutics (CGEM) in the next-generation EGFR inhibitor market for NSCLC, concluding BDTX is the better investment. BDTX's lead candidate, silevertinib, is in Phase II with frontline results due late 2025, while CGEM's zipalertinib met its Phase IIb endpoint, with Taiho planning a 2025 NDA filing. BDTX shares have surged 59.8% YTD against CGEM's 48.4% decline, with BDTX also trading at a significantly cheaper 5.87x forward sales compared to CGEM's 15.56x, supported by positive EPS estimate revisions.

Analysis

A comparative analysis of Black Diamond Therapeutics (BDTX) and Cullinan Therapeutics (CGEM) reveals diverging investor sentiment and fundamentals despite both competing in the non-small cell lung cancer (NSCLC) EGFR inhibitor market. BDTX has demonstrated significant market outperformance, with its stock surging 59.8% year-to-date, while CGEM has declined 48.4% against a 5.2% industry gain. This performance divergence is supported by underlying financial metrics and analyst sentiment. BDTX's 2025 EPS estimates have been revised upward, projecting 125.98% growth, and it trades at a more attractive valuation of 5.87x forward sales. In contrast, CGEM's EPS estimates for 2025 and 2026 have moved south, and it trades at a premium valuation of 15.56x forward sales. Clinically, BDTX's sole focus is its lead candidate, silevertinib, a fourth-generation inhibitor with a broad target profile that includes the C797S resistance mutation, with initial frontline Phase II results anticipated in late 2025. Conversely, CGEM's zipalertinib, co-developed with Taiho, has already met its Phase IIb endpoint, and Taiho plans an NDA submission by the end of 2025, suggesting a shorter timeline to potential approval for its specific indication. However, the market is currently favoring BDTX's perceived long-term potential and favorable financial profile over CGEM's nearer-term regulatory milestone and broader, but less favored, pipeline.

Key Decisions for Investors

• Given BDTX's strong stock momentum, positive estimate revisions, and significantly lower valuation multiple relative to CGEM, investors may find its risk/reward profile more attractive, especially considering silevertinib's potential to address post-Tagrisso resistance.
• Investors in BDTX should closely monitor key upcoming catalysts, namely the initial frontline Phase II data in Q4 2025 and FDA feedback in H1 2026, as these events are critical for validating the company's single-asset strategy.
• Despite CGEM's significant underperformance and downward estimate revisions, its partner's plan to file an NDA for zipalertinib by late 2025 presents a potential contrarian opportunity, but the stock's high valuation and negative sentiment carry substantial risk.
• The out-licensing of its second asset has made BDTX a pure-play on silevertinib, increasing its dependency on a single clinical outcome and making it a higher-risk, higher-reward proposition compared to the more diversified pipeline of CGEM.